Free Trial

Ionis Pharmaceuticals Q2 2024 Earnings Report

Ionis Pharmaceuticals logo
$35.63 +0.04 (+0.11%)
(As of 12/20/2024 05:31 PM ET)

Ionis Pharmaceuticals EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.92
Beat/Miss
Beat by +$0.47
One Year Ago EPS
$0.60

Ionis Pharmaceuticals Revenue Results

Actual Revenue
$225.00 million
Expected Revenue
$152.35 million
Beat/Miss
Beat by +$72.65 million
YoY Revenue Growth
+19.70%

Ionis Pharmaceuticals Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

Ionis Pharmaceuticals Earnings Headlines

Ionis stock rises following FDA approval of TRYNGOLZA
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
Ionis gets FDA approval for Tryngolza
See More Ionis Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ionis Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ionis Pharmaceuticals and other key companies, straight to your email.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals (NASDAQ:IONS) discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

View Ionis Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings